'Tremendous' animal data inspire GV, ARCH's $63M booster for Sekar Kathiresan's drive to relegate coronary heart disease to history
In the year since Sekar Kathiresan drew the curtain on Verve Therapeutics and its goal to end the chronic care approach to coronary heart disease, the academic-turned-CEO has quadrupled his team and accrued what he calls “tremendous data” — including a glimpse at how its gene editing medicine might work in non-human primates in vivo.
Just exactly what that means will only be revealed to the world at a conference later this month. But the investors who had an inside view are happy enough to pony up another $63 million to get the startup through to first-in-human studies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.